In the evolving field of biochemical research, the peptide CIGB-552 has emerged as a subject of significant interest for those tracking advancements in synthetic amino by ХРФ Массо · 2025 — by the Synthetic Peptide CIGB-552 and Its Relationship with Tumor Cell Line Sensitivity. Molecules. 2018 Mar 30;23(4):801. https://doi.org/10.3390 acid chains. As someone who follows developments in molecular biology and biotechnology, I have found the structural complexity and functional properties of this specific compound to be quite remarkable.
Understanding the Structure of CIGB-552
At its core, CIGB-552 is a twenty-amino-acid novel synthetic peptide. It is classified as a second-generation peptide CIGB-552, which signifies an evolution in design compared to its predecessor, the L-2 peptide. Developed at the Center for Genetic Engineering and Biotechnology, the molecular architecture of this compound allows it to function as a cell-penetrating peptide. This ability to traverse cellular membranes is a critical feature that differentiates it from simpler compounds.
When reviewing the technical literature, it is clear that CIGB-552 is a synthetic peptide designed with specific biochemical interactions in mind. by B Simonneau · 2025 · Cited by 1 — Although not a corrector or potentiator alone, CIGB-552 synergised with ETI, enhancing CFTR-F508del-mediated chloride efflux, confirmed in One of the most frequently cited mechanisms is that CIGB-552 increases the levels of the protein COMMD1. By upregulating this protein, the peptide is able to interact with internal cellular pathways in a highly targeted manner.
Biochemical Mechanisms and Observations
My interest in this 552 peptide grew after reading about its impact on cellular regulation. For instance, research indicates that CIGB-552 induces ubiquitination of RelA, a process that effectively modulates the activity of the NF-kB pathway. Furthermore, the molecule act CIGB-552 is a cell-penetrating peptide with anti-tumor properties with the IC50 of 23 μM in H460 cells. CIGB-552 can increase the level of protein COMMD1. s as a new targeted anticancer therapy in experimental settings, showing potential in laboratory models where it has been observed to reduce tumor size and extend the lifespan o by NA Gómez · 2025 — CIGB-552 presented a typical extravascular administration profile with rapid absorption, along with a rapid tissue distribution phase and rapid blood clearance. f subjects.
From a pharmacokinetic perspective, the data is equally compelling. Studies show that CIGB-552 exhibits rapid absorption (within 15 min), which is essential for its observed activity profiles. It maintains a typical extravascular CIGB-552 peptide · * 5.0 mg (TFA removed) · 20.0 mg (TFA removed). * Buy 1 get 1 free (?). Special Price 207.80 USD. administration profile followed by a swift distribution phase. With a reported half-life ranging between 1.76 and 4.62 hours, the CIGB-552 molecule is optimized for specific, frequent dosing regimens in controlled research environments.
Synergistic Potential and Modern Research
Beyond its primary functions, there is growing intrigue regarding how this compound interacts with other agents. Recent reports suggest th Process of generation of antitumor peptide CIGB‐552. The at CIGB-552 synergised with ETI, enhancing CFTR-F508del-mediated ch by BM Oliva · 2013 · Cited by 1 — We found that CIGB-552 induces ubiquitination of RelA and inhibits the anti-apoptotic genes regulated by NF-kB whereas knockdown of COMMD1 blocks this effect. loride efflux. This CIGB-552 synergy with the tri-therapy highlights the versatility of this CIGB derivative, suggesting that its utility might extend beyond initial expectations.
As a second-generation synthetic anticancer peptide, its development has been rigorous. Whether it is classified as a synthetic anti-tumor peptide or simply a 552 molecule, the consistency of the findings—such as its role in increasing reactive oxygen species (ROS) and its interaction with COMMD1—remains a cornerstone of its profile.
Conclusion on CIGB-552
Whether you are looking at it as a CIGB-552 or a broader Synthetic Peptide CIGB-552, the compound represents a sophisticated achievement in synthetic biology. It is important to note that this information is intended for educational purposes regarding the chemical properties and research status of the molecule. It has been developed as a candidate to cancer treatment within the framework of rigorous clinical trials, such as the first-in-human phase I studies, which focused on safety and pharmacokinetic parameters.
For those of us observing the progress of the CIGB-552 peptide, the focus remains on its unique ability to penetrate cells and modulate protein levels, positioning it as a significant entity in the study of modern biochemistry.